iData Insights

Cedar Pollen Allergy - Pipeline Review, H2 2015 Is Released Is Released

Press Release   •   Jan 30, 2016 12:23 IST

Cedar Pollen Allergy - Pipeline Review, H2 2015 Summary Global Markets Direct s, Cedar Pollen Allergy - Pipeline Review, H2 2015 , provides an overview of the Cedar Pollen Allergy s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. Global Markets Direct s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 5

Global Markets Direct Report Coverage 5

Cedar Pollen Allergy Overview 6

Therapeutics Development 7

Pipeline Products for Cedar Pollen Allergy - Overview 7

Pipeline Products for Cedar Pollen Allergy - Comparative Analysis 8

Cedar Pollen Allergy - Therapeutics under Development by Companies 9

Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes 10

Cedar Pollen Allergy - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Cedar Pollen Allergy - Products under Development by Companies 13

Cedar Pollen Allergy - Products under Investigation by Universities/Institutes 14

Cedar Pollen Allergy - Companies Involved in Therapeutics Development 15

Anergis SA 15

Biomay AG 16

Circassia Pharmaceuticals Plc 17

Immunomic Therapeutics, Inc. 18

Japan Tobacco Inc. 19

REGiMMUNE Corporation 20

Cedar Pollen Allergy - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

AllerJ - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ASP-4070 - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Drugs for Cedar Pollen Allergy - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

japanese cedar hypoallergenic vaccine - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

JCC-LAMP-Vax - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

MC-LAMP-Vax - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

RGI-1001 - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

TO-206 - Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Vaccine for Cedar Pollen Allergy - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Vaccine for Japanese Cedar Pollen Allergy - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Cedar Pollen Allergy - Recent Pipeline Updates 38

Cedar Pollen Allergy - Dormant Projects 40

Cedar Pollen Allergy - Product Development Milestones 41

Featured News & Press Releases 41

Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference 41

Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting 41

Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study To Treat Japanese Red Cedar Allergy 42

Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy 42

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects